Corbus obesity trial shows 5% weight loss with CRB-913 at 12 weeks
CANYON-1 phase I-B data for CRB-913 in obesity reported 5% average weight loss at 12 weeks, with mild and transient psychiatric and GI side effects and a favorable safety profile; additional studies are planned.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.